Moreover, ICT exerts its anti-HCC effects, at least in part, by downregulating the expression of CA9, UCK2, and FABP5 while upregulating CYP2C9, thereby validating these four genes as robust prognostic biomarkers and potential therapeutic targets. The gene discussed is FABP5; the disease is hepatocellular carcinoma.